EGFR-Targeted Therapy in NSCLC LC
Symposium
Symposium

EGFR-Targeted Therapy in NSCLC LC

EGFR-Targeted Therapy in NSCLC Leptomeningeal Carcinomatosis

Not a member of My prIME? Join now for instant access.

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

Meeting Overview

Understand the role of the neuro-oncologist and enhance your understanding of leptomeningeal carcinomatosis in non-small cell lung cancer (NSCLC) at this interactive satellite symposium. A variety of topics will be discussed, including incidence of leptomeningeal carcinomatosis, patient presentation and prognostic factors, and limitations of traditional therapies. There will be a focus on the efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs) when leptomeningeal carcinomatosis is present. In addition, practical considerations in the treatment of leptomeningeal carcinomatosis with EGFR-targeted therapy, such as testing for EGFR mutation on progression, monitoring leptomeningeal carcinomatosis response to EGFR TKI therapy, dosing and duration of EGFR therapy, management of adverse events, and the importance of interdisciplinary communication, will be discussed. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Date and Location

Saturday, November 18, 2017
12.15 PM – 1.15 PM

Nob Hill CD
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California 94103

Date/Time

Date/Time

Saturday, November 18, 2017
12.15 PM – 1.15 PM

Location

Location

San Francisco, California, United States

CME

CME

1.0 AMA PRA Category 1 Credit

Saturday, November 18, 2017

12.15 PM Welcome and quiz questions
Manmeet Ahluwalia, MD, FACP
12.20 PM Leptomeningeal carcinomatosis in non-small cell lung cancer (NSCLC): The scope of the challenge
Jeremy Rudnick, MD
12.30 PM Examining strategies for leptomeningeal carcinomatosis in EGFR-mutant NSCLC
Heather Wakelee, MD
12.45 PM Question and answer panel
12.50 PM Panel discussion: Practical considerations in the treatment of leptomeningeal carcinomatosis with EGFR-targeted therapy
All Faculty
1.05 PM Question and answer panel
1.10 PM prIME Points™
Manmeet Ahluwalia, MD, FACP
1.15 PM Adjourn

    Chair

  • Manmeet Ahluwalia, MD, FACPCleveland Clinic
    Cleveland, Ohio, United States
  • Faculty

  • Jeremy Rudnick, MDCedars-Sinai Medical Center
    Los Angeles, California, United States
  • Heather Wakelee, MDStanford University
    Stanford, California, United States

This educational activity is specifically designed to meet the needs of neuro-oncologists, medical oncologists, and other healthcare professionals providing care to patients with leptomeningeal carcinomatosis in NSCLC.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the efficacy of EGFR TKIs in the treatment of leptomeningeal carcinomatosis in NSCLC in recent trials
  • Identify and manage potential treatment-related adverse events associated with EGFR TKIs

This educational activity is supported by a grant from AstraZeneca.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.